2024
Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the IeDEA consortium
Lancaster K, Stockton M, Remch M, Wester C, Nash D, Brazier E, Adedimeji A, Finlayson R, Freeman A, Hogan B, Kasozi C, Kwobah E, Kulzer J, Merati T, Tine J, Poda A, Succi R, Twizere C, Tlali M, von Groote P, Edelman E, Parcesepe A, Consortium I. Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the IeDEA consortium. International Journal Of Drug Policy 2024, 124: 104309. PMID: 38228025, PMCID: PMC10939808, DOI: 10.1016/j.drugpo.2023.104309.Peer-Reviewed Original ResearchAlcohol use disorder screeningHIV clinical sitesHIV care settingsProportion of clinicsSubstance use disordersAlcohol use disorderBrief interventionHIV careCare settingsClinical sitesSubstance use disorder screeningTreatment availabilityNegative impact of substance useHIV clinical settingsAvailability of screeningReferral to treatmentInternational epidemiology DatabasesHigh-income countiesImpact of substance useLower-middle-income countriesTreat alcohol use disorderUpper-middle income countriesLow-income countriesEpidemiological databasePrevalence estimatesPerspectives of clinical stakeholders and patients from four VA liver clinics to tailor practice facilitation for implementing evidence-based alcohol-related care
Soyer E, Frost M, Fletcher O, Ioannou G, Tsui J, Edelman E, Weiner B, Bachrach R, Chen J, Williams E. Perspectives of clinical stakeholders and patients from four VA liver clinics to tailor practice facilitation for implementing evidence-based alcohol-related care. Addiction Science & Clinical Practice 2024, 19: 3. PMID: 38200496, PMCID: PMC10782537, DOI: 10.1186/s13722-023-00429-3.Peer-Reviewed Original ResearchConceptsConsolidated Framework for Implementation ResearchAlcohol-related careVeterans Health AdministrationRapid Assessment ProcessClinical stakeholdersPatient participationImplement interventionsBackgroundUnhealthy alcohol useLiver clinicEvidence-based strategiesClinical settingPractice facilitationProvider beliefsImplementation researchHealth AdministrationMethodsData collectionClinical resourcesQualitative interviewsAlcohol use disorderEducation-basedCareAlcohol useMedical CenterPreference-basedRelationship-based
2023
Expanding the Use of Medications for Alcohol Use Disorder: Lessons from the Proliferation of Anti-obesity Medications
Bernstein E, Moreno J, Edelman E. Expanding the Use of Medications for Alcohol Use Disorder: Lessons from the Proliferation of Anti-obesity Medications. Journal Of General Internal Medicine 2023, 39: 1233-1235. PMID: 38087177, PMCID: PMC11116289, DOI: 10.1007/s11606-023-08565-x.Peer-Reviewed Original ResearchFacilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial
Muvvala S, Gan G, Morford K, Dziura J, Esserman D, Porter E, Chan P, Cornman D, Reynolds J, Yager J, Fiellin D, Edelman E. Facilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial. Journal Of Addiction Medicine 2023, 17: e388-e391. PMID: 37934538, PMCID: PMC10726383, DOI: 10.1097/adm.0000000000001192.Peer-Reviewed Original ResearchConceptsOpioid use disorderAlcohol use disorderTobacco use disorderHIV clinicUse disordersAddiction treatmentSubstance use disorder treatmentUse disorder treatmentMaintenance phaseRandomized trialsStaff preferencesImproved outcomesMultisite Randomized TrialImplementation facilitationDisorder treatmentControl phaseClinicCliniciansTreatment modelTreatmentDisordersSignificant differencesInterventionHigher proportionAddiction treatment modelsPromoting alcohol treatment engagement post-hospitalization with brief intervention, medications and CBT4CBT: protocol for a randomized clinical trial in a diverse patient population
Edelman E, Rojas-Perez O, Nich C, Corvino J, Frankforter T, Gordon D, Jordan A, Paris, Jr M, Weimer M, Yates B, Williams E, Kiluk B. Promoting alcohol treatment engagement post-hospitalization with brief intervention, medications and CBT4CBT: protocol for a randomized clinical trial in a diverse patient population. Addiction Science & Clinical Practice 2023, 18: 55. PMID: 37726823, PMCID: PMC10510167, DOI: 10.1186/s13722-023-00407-9.Peer-Reviewed Original ResearchConceptsPost-hospital dischargeCognitive behavioral therapySelf-reported alcohol useBrief Negotiation InterviewUse disordersAlcohol use outcomesComputer-based trainingDays post-hospital dischargeAlcohol use disorderBehavioral therapyInitiation of medicationHealth care utilizationHealth promotion advocatesTreatment engagementUse outcomesAlcohol useSecondary outcomesHospitalized patientsPrimary outcomeCare utilizationClinical trialsAcademic hospitalExploratory outcomesAUDProcess evaluation
2022
Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, Tetrault J, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Network Open 2022, 5: e2246604. PMID: 36515952, PMCID: PMC9856353, DOI: 10.1001/jamanetworkopen.2022.46604.Peer-Reviewed Original ResearchConceptsCurrent alcohol use disorderLow-risk drinkingAlcohol use disorderVeterans Health AdministrationHistory of AUDDAA treatmentAlcohol use categoriesAUD historyCohort studyRisk drinkingUse disordersDirect acting antiviral (DAA) treatmentAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionHepatitis C virus (HCV) treatmentCox proportional hazards regressionC virus infectionC virus treatmentProportional hazards regressionTenth Revision diagnosisAUDIT-C questionnaireInternational Statistical ClassificationRelated Health ProblemsAntiviral treatmentRevision diagnosis
2016
Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. PMID: 27431048, PMCID: PMC4976086, DOI: 10.1016/j.jsat.2016.06.002.Peer-Reviewed Original ResearchConceptsLiver enzyme elevationAlcohol use disorderUninfected patientsHepatotoxic medicationsHCV infectionUse disordersComposite endpointLiver injuryHIV/HCV co-infected patientsHCV co-infected patientsHIV/HCV statusPre-existing liver injuryCo-infected patientsCohort of HIVHepatitis C infectionHIV/HCVOpioid use disorderRisk of hepatotoxicityHCV statusHepatic safetyMedian ALTC infectionChart reviewEnzyme elevationHIV infection